Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The traditional risk factors for obesity are inappropriate diet, lack of exercise and genetic factors. However, recent observations have involved gut microbiota profiles as having an additional influence. In this case, there exists the possibility to modulate this through diet. Research has shown that the gut microbiota of both obese humans and mouse models of obesity is altered towards less beneficial one compared to lean counterparts. This raises the possibility of modulating the gut microbiota as a novel strategy in tackling the epidemic of obesity and diabetes sweeping the developed world. In addition, a more direct effect of high-fat induced disruption of the intestinal microbiota has also been seen with a murine model. Elevated circulating levels of lipopolysaccharide (LPS) a major building block and antigen of Gram-negative bacteria, was shown to generate a low grade chronic inflammation, termed metabolic endotoxemia, which then onsets insulin resistance. High-fat diets were shown to disrupt the Gram-negative intestinal populations of these animals, liberating LPS. The effects of prebiotics on the microbiota or metabolic syndrome (combination of disorders that increase the risk of developing cardiovascular disease and diabetes) in overweight adults have not been investigated thus far. The investigators therefore propose to investigate the effect of galactooligosaccharide (GOS) on the faecal microbiota and metabolic syndrome risk factors in overweight adults in a double-blind, randomised, placebo controlled, cross-over trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Nutritional Intervention With Probiotics and Prebiotics on Obesity.

NCT06722443

Obesity and Overweight Obesity, Morbid Metabolic Syndrome

ENROLLING_BY_INVITATION NA

The Effect of Prebiotic B-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People

NCT01303484

Immunosenescence

COMPLETED EARLY_PHASE1

Probiotics on Body Composition and Insulin Resistance in Patients With Obesity and Its Association With Gut Microbiota

NCT04086173

Obesity Insulin Resistance Microbial Colonization

UNKNOWN NA

Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity

NCT02733484

Obesity

UNKNOWN NA

A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers

NCT01545219

Gut Microbiota Bowel Function Immune Function +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MDn

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

5.5g daily intake

B-GOS

Group Type ACTIVE_COMPARATOR

Bimuno

Intervention Type DIETARY_SUPPLEMENT

5.5g daily intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bimuno

5.5g daily intake

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

5.5g daily intake

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Galactooligosaccharide Dexrins

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-65y
* BMI \>25 kg/m2

Exclusion Criteria

* Suffered from a myocardial infarction/stroke or cancer in the past 12 months
* Diabetic or suffering from endocrine disorders
* Suffer from renal or bowel disease/gut disorder or have a history of cholestatic jaundice or pancreatitis
* Requirements to take long-term medication for hyperlipidaemia, hypertension, inflammation or hypercoagulation
* History of alcohol or drug abuse
* Planning or on a weight reducing regime
* Taking antioxidant (or phytochemical), probiotic or prebiotics supplements
* Pregnant or lactating women or those planning pregnancy in the next 6 months or of child-bearing age who are not using contraception
* Use of antibiotics within the previous 1 month
* Anemic
* Smoker

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes